molecules of the month

“compound 25”

mutant KRASG12C allosteric covalent inhibitor

orally efficacious in XG model

from optimization of literature starting point

J. Med. Chem. Feb. 5, 2020

AstraZeneca, Cambridge, UK

"compound 25"
1 min read

KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: